Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World

Iguratimod (IGU) is a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) routinely prescribed in Japan since 2012 to patients with rheumatoid arthritis (RA). Iguratimod acts directly on B cells by inhibiting the production of inflammatory cytokines (tumor necrosis factor-α, inter...

Descripción completa

Detalles Bibliográficos
Autor principal: Nozaki, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160848/
https://www.ncbi.nlm.nih.gov/pubmed/34065413
http://dx.doi.org/10.3390/life11050457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160848/
https://www.ncbi.nlm.nih.gov/pubmed/34065413
http://dx.doi.org/10.3390/life11050457

Ejemplares similares